Secondary amyloidosis electrocardiogram: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
* An [[ECG]] may be helpful in the [[diagnosis]] of secondary amyloidosis. Findings on an [[ECG]] suggestive of [[cardiac]] involvement include:<ref name="Real de AsuaGalvan2014">{{cite journal|last1=Real de Asua|first1=Diego|last2=Galvan|first2=Jose Maria|last3=Filigghedu|first3=Maria Teresa|last4=Trujillo|first4=Davinia|last5=Costa|first5=Ramon|last6=Cadinanos|first6=Julen|title=Systemic AA amyloidosis: epidemiology, diagnosis, and management|journal=Clinical Epidemiology|year=2014|pages=369|issn=1179-1349|doi=10.2147/CLEP.S39981}}</ref> | * An [[ECG]] may be helpful in the [[diagnosis]] of secondary amyloidosis. Findings on an [[ECG]] suggestive of [[cardiac]] involvement include:<ref name="Real de AsuaGalvan2014">{{cite journal|last1=Real de Asua|first1=Diego|last2=Galvan|first2=Jose Maria|last3=Filigghedu|first3=Maria Teresa|last4=Trujillo|first4=Davinia|last5=Costa|first5=Ramon|last6=Cadinanos|first6=Julen|title=Systemic AA amyloidosis: epidemiology, diagnosis, and management|journal=Clinical Epidemiology|year=2014|pages=369|issn=1179-1349|doi=10.2147/CLEP.S39981}}</ref> | ||
** Voltage is lower than 5 mm in all limb leads. | ** Voltage is lower than 5 mm in all limb leads. | ||
* Other possible findings include: | |||
**[[Left ventricle|Left ventricular]] [[Hypertrophy (medical)|hypertrophy]]<ref name="pmid25743445">{{cite journal| author=Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J| title=Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. | journal=J Cardiovasc Transl Res | year= 2015 | volume= 8 | issue= 2 | pages= 117-27 | pmid=25743445 | doi=10.1007/s12265-015-9613-9 | pmc=4382536 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25743445 }} </ref> | |||
**[[Right ventricle|Right ventricular]] hypertrophy<ref name="pmid25743445">{{cite journal| author=Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J| title=Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. | journal=J Cardiovasc Transl Res | year= 2015 | volume= 8 | issue= 2 | pages= 117-27 | pmid=25743445 | doi=10.1007/s12265-015-9613-9 | pmc=4382536 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25743445 }} </ref> | |||
**[[Left atrium|Left atrial]] abnormalities | |||
*Pathological [[Q waves]]<ref name="pmid25743445">{{cite journal| author=Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J| title=Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. | journal=J Cardiovasc Transl Res | year= 2015 | volume= 8 | issue= 2 | pages= 117-27 | pmid=25743445 | doi=10.1007/s12265-015-9613-9 | pmc=4382536 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25743445 }} </ref> | |||
**[[Atrioventricular block]]: [[Atrioventricular block|AV block]] occur due to deposition of amyloid fibrils in the conduction [[Tissue (biology)|tissue]]. | |||
* [[Cardiac]] involvement rarely occurs in the secondary amyloidosis and other possible cause should be ruled out first.<ref name="PapaLachmann2018">{{cite journal|last1=Papa|first1=Riccardo|last2=Lachmann|first2=Helen J.|title=Secondary, AA, Amyloidosis|journal=Rheumatic Disease Clinics of North America|volume=44|issue=4|year=2018|pages=585–603|issn=0889857X|doi=10.1016/j.rdc.2018.06.004}}</ref> | * [[Cardiac]] involvement rarely occurs in the secondary amyloidosis and other possible cause should be ruled out first.<ref name="PapaLachmann2018">{{cite journal|last1=Papa|first1=Riccardo|last2=Lachmann|first2=Helen J.|title=Secondary, AA, Amyloidosis|journal=Rheumatic Disease Clinics of North America|volume=44|issue=4|year=2018|pages=585–603|issn=0889857X|doi=10.1016/j.rdc.2018.06.004}}</ref> | ||
Revision as of 23:45, 29 October 2019
|
Secondary amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Secondary amyloidosis electrocardiogram On the Web |
|
American Roentgen Ray Society Images of Secondary amyloidosis electrocardiogram |
|
Risk calculators and risk factors for Secondary amyloidosis electrocardiogram |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]
Overview
An ECG may be helpful in the diagnosis of secondary amyloidosis.
Electrocardiogram
- An ECG may be helpful in the diagnosis of secondary amyloidosis. Findings on an ECG suggestive of cardiac involvement include:[1]
- Voltage is lower than 5 mm in all limb leads.
- Other possible findings include:
- Left ventricular hypertrophy[2]
- Right ventricular hypertrophy[2]
- Left atrial abnormalities
- Pathological Q waves[2]
- Atrioventricular block: AV block occur due to deposition of amyloid fibrils in the conduction tissue.
- Cardiac involvement rarely occurs in the secondary amyloidosis and other possible cause should be ruled out first.[3]
References
- ↑ Real de Asua, Diego; Galvan, Jose Maria; Filigghedu, Maria Teresa; Trujillo, Davinia; Costa, Ramon; Cadinanos, Julen (2014). "Systemic AA amyloidosis: epidemiology, diagnosis, and management". Clinical Epidemiology: 369. doi:10.2147/CLEP.S39981. ISSN 1179-1349.
- ↑ 2.0 2.1 2.2 Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J (2015). "Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis". J Cardiovasc Transl Res. 8 (2): 117–27. doi:10.1007/s12265-015-9613-9. PMC 4382536. PMID 25743445.
- ↑ Papa, Riccardo; Lachmann, Helen J. (2018). "Secondary, AA, Amyloidosis". Rheumatic Disease Clinics of North America. 44 (4): 585–603. doi:10.1016/j.rdc.2018.06.004. ISSN 0889-857X.